BRAIN and NERVE－神経研究の進歩68巻7号

2016年07月発行

増大特集 認知症の危険因子と防御因子

アポリポ蛋白E遺伝子（APOE）

著者： 徳武孝允¹ 春日健作²³ 原範和² 池内健²

所属機関： ¹新潟大学脳研究所神経内科 ²新潟大学脳研究所遺伝子機能解析学 ³新潟大学研究推進機構超域学術院

ページ範囲：P.703 - P.712

文献概要

アポリポ蛋白E遺伝子（APOE）はアルツハイマー病（AD）の強力な感受性遺伝子である。APOEε4はAD発症リスクとなる一方，ε2は防御的に作用する。遺伝的リスクとしてのAPOEの役割に加え，APOE多型は健常者の認知機能，画像・バイオマーカー所見に関与する。APOEε4保因者では脳内アミロイド蓄積が早発化することから，ε4はADの病態早期に作用する可能性がある。APOEε4陽性の健常高齢者をAD発症の高リスク者として抽出し，予防介入を試みる探索的治験が海外で行われている。

参考文献

1)Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K: Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillarytangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541: 163-166, 1991

2)Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, et al: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90: 1977-1981, 1993

3)Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE: Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39: 17-23, 2007

4)Shore VG, Shore B: Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components. Biochemistry 12: 502-507, 1973

5)Mahley RW, Rall SC Jr: Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1: 507-537, 2000

6)DeMattos RB, Brendza RP, Heuser JE, Kierson M, Cirrito JR, et al: Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochem Int 39: 415-425, 2001

7)Kim J, Basak JM, Holtzman DM: The role of apolipoprotein E in Alzheimer's disease. Neuron 63: 287-303, 2009

8)Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, et al: Profile and regulation of apolipoprotein E (apoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the apoE locus. J Neurosci 26: 4985-4994, 2006

9)Kanekiyo T, Xu H, Bu G: ApoE and Aβ in Alzheimer's disease: accidental encounters or partners? Neuron 81: 740-754, 2014

10)Dong LM, Parkin S, Trakhanov SD, Rupp B, Simmons T, et al: Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol 3: 718-722, 1996

11)Dong LM, Weisgraber KH: Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J Biol Chem 271: 19053-19057, 1996

12)Eisenberg DT, Kuzawa CW, Hayes MG: Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am J Phys Anthropol 143: 100-111, 2010

13)Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923, 1993

14)Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, et al: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 278: 1349-1356, 1997

15)Takei N, Miyashita A, Tsukie T, Arai H, Asada T, et al: Genetic association study on in and around the APOE in late-onset Alzheimer disease in Japanese. Genomics 93: 441-448, 2009

16)Miyashita A, Wen Y, Kitamura N, Matsubara E, Kawarabayashi T, et al: Lack of genetic association between TREM2 and late-onset Alzheimer's disease in a Japanese population. J Alzheimers Dis 41: 1031-1038, 2014

17)Liu CC, Kanekiyo T, Xu H, Bu G: Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9: 106-118, 2013

18)Damoiseaux JS, Seeley WW, Zhou J, Shirer WR, Coppola G, et al; Alzheimer's Disease Neuroimaging Initiative: Gender modulates the APOE ε4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci 32: 8254-8262, 2012

19)Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, et al: Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45: 1452-1458, 2013

20)Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, et al: Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 65: 650-657, 2009

21)Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, et al: Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 3: 89ra57, 2011

22)Ma J, Yee A, Brewer HB Jr, Das S, Potter H: Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372: 92-94, 1994

23)Wood SJ, Chan W, Wetzel R: Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 35: 12623-12628, 1996

24)Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, et al: Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J Neurosci 32: 15181-15192, 2012

25)LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, et al: Isoform-specific binding of apolipoprotein E to β-amyloid. J Biol Chem 269: 23403-23406, 1994

26)Koistinaho M, Lin S, Wu X, Esterman M, Koger D, et al: Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 10: 719-726, 2004

27)Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, et al: ApoE promotes the proteolytic degradation of Aβ. Neuron 58: 681-693, 2008

28)Deane R, Sagare A, Hamm K, Parisi M, Lane S, et al: ApoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J Clin Invest 118: 4002-4013, 2008

29)Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, et al: Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A 100: 10966-10971, 2003

30)Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, et al: Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A 98: 8838-8843, 2001

31)Chang S, Ma TR, Miranda RD, Balestra ME, Mahley RW, et al: Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci U S A 102: 18694-18699, 2005

32)Dumanis SB, Tesoriero JA, Babus LW, Nguyen MT, Trotter JH, et al: ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci 2: 15317-15322, 2009

33)Hafezi-Moghadam A, Thomas KL, Wagner DD: ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage. Am J Physiol Cell Physiol 29: C1256-C1262, 2007

34)Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M: Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J Biol Chem 286: 17536-17542, 2011

35)Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, et al: Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485: 512-516, 2012

36)Ohm TG, Scharnagl H, März W, Bohl J: Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol 98: 273-280, 1999

37)Lanz TA, Carter DB, Merchant KM: Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis 13: 246-253, 2003

38)Shinohara M, Kanekiyo T, Yang L, Linthicum D, Shinohara M, et al: APOE2 eases cognitive decline during aging: clinical and preclinical evaluations. Ann Neurol, 2016 Mar 2［Epub ahead of print］

39)Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, et al: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-128, 2010

40)Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, et al: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65: 403-413, 2009

41)Reiman EM, Chen K, Liu X, Bandy D, Yu M, et al: Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106: 6820-6825, 2009

42)Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, et al: No association of CSF biomarkers with APOEε4, plaque and tangle burden in definite Alzheimer's disease. Brain 130: 2320-2326, 2007

43)Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, et al: Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 67: 308-316, 2010

44)Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, et al: Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry 71: 1183-1191, 2014

45)Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, et al: APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67: 122-131, 2010

46)Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, et al: Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313: 1924-1938, 2015

47)Mattsson N, Insel PS, Palmqvist S, Stomrud E, van Westen D, et al: Increased amyloidogenic APP processing in APOE ε4-negative individuals with cerebral β-amyloidosis. Nat Commun 7: 10918, 2016

48)Risacher SL, Kim S, Nho K, Foroud T, Shen L, et al: APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimers Dement 11: 1417-1429, 2015

49)Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, et al: Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79: 110-119, 2016

50)Schöll M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, et al: PET imaging of tau deposition in the aging human brain. Neuron 89: 971-982, 2016

51)Jack CR Jr, Petersen RC, Xu YC, O'Brien PC, Waring SC, et al: Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol 43: 303-310, 1998

52)Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, et al: MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 132: 1067-1077, 2009

53)Jack CR Jr, Wiste HJ, Weigand SD, Knopman DS, Vemuri P, et al: Age, sex, and APOE ε4 effects on memory, brain structure, and beta-amyloid across the adult life span. JAMA Neurol 72: 511-519, 2015

54)Protas HD, Chen K, Langbaum JB, Fleisher AS, Alexander GE, et al: Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol 70: 320-325, 2013

55)Drzezga A, Riemenschneider M, Strassner B, Grimmer T, Peller M, et al: Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology 64: 102-107, 2005

56)Wirth M, Villeneuve S, La Joie R, Marks SM, Jagust WJ: Gene-environment interactions: lifetime cognitive activity, APOE genotype, and beta-amyloid burden. J Neurosci 34: 8612-8617, 2014

57)Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Machulda M, et al: Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study. Neurology 86: 1128-1135, 2016

58)Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, et al: Longitudinal modeling of age-related memory decline and the APOE ε4 effect. N Engl J Med 361: 255-263, 2009

59)Langbaum JB, Hendrix S, Ayutyanont N, Bennett DA, Shah RC, et al: Establishing composite cognitive endpoints for use in preclinial Alzheimer's disease trials. J Prev Alzheimers Dis 2: 2-3, 2015